BRIEF-Catalyst Pharmaceuticals gets FDA special protocol assessment for phase 3 trial of lems treatment
October 31, 2016 at 09:20 AM EDT
* Says intends to conduct its second phase 3 trial (designated as lms-003) at two clinical trial sites
